{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00157703",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CT2001"
      },
      "Organization": {
        "OrgFullName": "MediGene",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "G207 Followed by Radiation Therapy in Malignant Glioma",
      "OfficialTitle": "A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2008",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2005"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2008",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2008",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "September 8, 2005",
      "StudyFirstSubmitQCDate": "September 8, 2005",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 12, 2005",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 12, 2008",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 16, 2008",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Alice Chen",
        "ResponsiblePartyOldOrganization": "MediGene"
      },
      "LeadSponsor": {
        "LeadSponsorName": "MediGene",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Cancer Institute (NCI)",
            "CollaboratorClass": "NIH"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.\n\nThis study is a two stage phase 1 study, in which a de-escalating dosing scheme will be used, i.e. the first patients will receive the higher dose and if excessive toxicity occurs, the dose will be reduced for the following patients. The purpose of the dose de-escalation phase is to find the best safe dose of G207.\n\nIn the first stage of the study, treatment with G207 will be followed by focal radiation therapy on the following day, and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day.\n\nAll patients will return to the clinic 28 days and 3, 6, 9 and 12 months after G207 administration at which time clinical assessments will be performed, and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Malignant Glioma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Malignant glioma",
          "Glioblastoma multiforme",
          "GBM",
          "Gliosarcoma",
          "Anaplastic astrocytoma",
          "Brain cancer",
          "Brain tumor",
          "Glioma",
          "recurrent/progressive malignant glioma"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "G207",
            "InterventionDescription": "1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)"
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse events",
            "PrimaryOutcomeTimeFrame": "from 1st dose to end of study visit"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Radiographic response",
            "SecondaryOutcomeTimeFrame": "Withdrawal or death of last patient"
          },
          {
            "SecondaryOutcomeMeasure": "Performance scale",
            "SecondaryOutcomeTimeFrame": "Last patient out"
          },
          {
            "SecondaryOutcomeMeasure": "Overall survival",
            "SecondaryOutcomeTimeFrame": "Withdrawal or death of last patient"
          },
          {
            "SecondaryOutcomeMeasure": "Immune response",
            "SecondaryOutcomeTimeFrame": "Last patient out"
          },
          {
            "SecondaryOutcomeMeasure": "Presence of G207 in blood and saliva",
            "SecondaryOutcomeTimeFrame": "Last patient out"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPathologically proven residual/recurrent glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma which is progressive despite radiotherapy or chemotherapy\nFailed external beam radiotherapy > 5,000 CGy at least 4 weeks prior to enrollment\nResidual/recurrent lesion must be ≥ 1.0 cm and (for Stage 2 only) ≤ 4 cm in diameter as determined by magnetic resonance imaging (MRI)\n\nNormal hematological, renal and liver function\n\nAbsolute neutrophil count > 1500/mm3\nPlatelets > 100,000/mm3\nProthrombin time (PT) or partial thromboplastin time (PTT) < 1.3 x control\nCreatinine < 1.7 mg/dl\nTotal bilirubin < 1.5 mg/dl\nTransaminases < 4 times above the upper limits of the institutional norm\nKarnofsky Performance Status score ≥ 70\nAge > 19 years-old\nCapable of giving informed consent\nMust be willing to practice an effective barrier method of birth control for 2 months post G207 inoculation, whether male or female\nFemales of childbearing potential: negative pregnancy test within 24 hours prior to G207 administration\n\nExclusion Criteria:\n\nSurgical resection within 4 weeks of enrolment\nAcute infection, granulocytopenia or medical condition precluding surgery\nPregnant or lactating females\nHistory of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection\nTumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatment or tumor involving both hemispheres or with subependymal/cerebral spinal fluid (CSF) dissemination\nTumor position that could, in the Investigator's opinion, pose the risk of penetration of the cerebral ventricular system during inoculation with the study drug (Note: If penetration of the ventricular system is suspected or confirmed, G207 administration must be aborted.)\nTumor locations that would expose the patient to unacceptable risk with radiation therapy\nPrior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpesvirus protocol)\nPrior participant in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment\nRequired steroid increase within 2 weeks prior to injection\nHIV seropositive\nConcurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir)\nActive oral or genital herpes lesion\nAny contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc.\nRadiation treatment volume of greater than 4 cm maximum diameter (Stage 2 only)",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "19 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Axel Mescheder, M.D.",
            "OverallOfficialAffiliation": "Medigene AG",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Alabama at Birmingham",
            "LocationCity": "Birmingham",
            "LocationState": "Alabama",
            "LocationZip": "35294-3410",
            "LocationCountry": "United States"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "24572293",
            "ReferenceType": "derived",
            "ReferenceCitation": "Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, Gillespie GY. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May;22(5):1048-55. doi: 10.1038/mt.2014.22. Epub 2014 Feb 27."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000005910",
            "ConditionMeshTerm": "Glioma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000018302",
            "ConditionAncestorTerm": "Neoplasms, Neuroepithelial"
          },
          {
            "ConditionAncestorId": "D000017599",
            "ConditionAncestorTerm": "Neuroectodermal Tumors"
          },
          {
            "ConditionAncestorId": "D000009373",
            "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009375",
            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
          },
          {
            "ConditionAncestorId": "D000009380",
            "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4361",
            "ConditionBrowseLeafName": "Brain Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8171",
            "ConditionBrowseLeafName": "Glioblastoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3713",
            "ConditionBrowseLeafName": "Astrocytoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8172",
            "ConditionBrowseLeafName": "Glioma",
            "ConditionBrowseLeafAsFound": "Malignant Glioma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19613",
            "ConditionBrowseLeafName": "Gliosarcoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19599",
            "ConditionBrowseLeafName": "Neoplasms, Neuroepithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18997",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19540",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11470",
            "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11472",
            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11477",
            "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2518",
            "ConditionBrowseLeafName": "Glioblastoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2519",
            "ConditionBrowseLeafName": "Glioma",
            "ConditionBrowseLeafAsFound": "Glioma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2522",
            "ConditionBrowseLeafName": "Gliosarcoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T364",
            "ConditionBrowseLeafName": "Anaplastic Astrocytoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4092",
            "ConditionBrowseLeafName": "Neuroepithelioma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}